Biotech Values

[DewDiligence]

Roughly half of the bolus of patients we’re talking about already took interferon and ribavirin in the first-line setting; the overwhelming majority (>=75%) of these patients ought to be able to take interferon/ribavirin with Telaprevir or Boceprevir in the second-line setting.

The other half of the bolus of patients we’re talking about consists of those who have never been treated. Unless these patients have a genetic variant known to cause a poor response to interferon/ribavirin, they too ought to be able to take a regimen of interferon/ribavirin with Telaprevir or Boceprevir.